Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Apr 22, 2026

Heico Corporation (HEI): Navigating the -14.6% Quarterly Decline and Key Technical Levels

Key Takeaways

  • HEI has experienced a sharp recent decline, trading below key moving averages including the 50-day SMA near 302 and 200-day SMA around 316, indicating short-term bearish momentum.
  • RSI(14) readings near 47 suggest neutral conditions on daily charts, while oversold levels around 27 on shorter timeframes point to potential bounce opportunities.
  • MACD shows negative values around -1.82 to -3.93 with sell signals, confirming downward pressure.
  • Pivot points highlight near-term support at 246-277 and resistance at 279-318.
  • Volume remains near average levels at approximately 630,000 shares daily, with no significant spikes noted recently.

Trend Analysis

From what I see with HEI, the stock has entered a short-term downtrend over the past quarter, dropping about 14.6% amid broader pressures in the aerospace sector. It recently broke below a five-month rectangle consolidation pattern, speeding up the decline from highs near 362 to current levels around 276-287. Year-to-date, HEI is still up 14.7%, maintaining a longer-term uptrend from the 52-week low of 241. Over the last 30 days, price action has been essentially flat at +0.01%, though a sharp single-day drop of over 5% underscores rising volatility. Weekly charts show a prevailing sell trend, while monthly signals tilt toward buy.

Support and Resistance Levels

Key support is building near recent pivot lows, with S1 levels at 246-277 across classic and Fibonacci pivots. The 52-week low around 241 acts as major downside protection. Resistance starts at the daily pivot near 278-291, then R1 at 279-319, and prior consolidation highs around 320-330. These zones match previous areas where buyers stepped in during pullbacks. One thing that stands out is that a break below 274 could lead to deeper supports, while reclaiming 290 might signal stabilization.

Moving Averages

HEI is trading below most major moving averages, which are flashing predominantly sell signals. The 10-day SMA is at 292, 20-day at 283-288, 50-day at 291-303, 100-day at 286-316, and 200-day at 284-316. Exponential MAs align similarly in bearish fashion, with price under the 10 EMA at 289 and 50 EMA at 299. I also checked this using Tickeron’s AI Screener to compare against industry peers, and this setup highlights the erosion of short-term bullish momentum—though a crossover above shorter MAs could hint at a reversal.

Momentum Indicators

The momentum indicators paint a mixed picture with oversold conditions emerging. RSI(14) is between 27 (oversold on Investing.com) and 47 (neutral on TradingView), pointing to potential exhaustion in selling. Stochastic and Williams %R are deeply oversold near 15 and -96, respectively, conditions that often lead to bounces. MACD(12,26) is negative at -1.82 to -3.93 with a sell signal, backed by a high ADX above 53 showing strong downward trend strength. CCI(14) at -109 adds to the sell bias, but oversold ultimate oscillator readings suggest possible short-term relief.

Volume and Market Activity

Daily trading volume for HEI averages around 629,000 shares, with recent sessions up slightly to 652,000 during the decline. There's no sign of major spikes or unusual activity, which fits with orderly selling rather than panic. This average volume bolsters the current consolidation near lows, and I'm watching for higher participation on any breakout moves.

Tickeron’s AI Daily Buy/Sell Signals

In my trading routine, I rely on Tickeron’s AI Daily Buy/Sell Signals to cut through the noise on stocks like HEI. These AI-powered signals draw from massive datasets of technical indicators, price patterns, and historical trends, spotting potential entry and exit points by detecting recurring market behaviors, continuations, and reversals via machine learning models trained on decades of data. They help me confirm chart setups and make sharper decisions in volatile times. If you're analyzing similar setups, checking these signals can add valuable AI-driven perspective to your strategy.

Technical Outlook and Key Levels to Watch

I'm keeping an eye on the oversold momentum for a possible rebound to resistance at 290-300, where moving averages converge. Holding above the 277 pivot could steady the chart, potentially targeting channel up retests near 320 with rising volume. On the flip side, a drop below 274 might push toward 241 support. Watch for RSI divergence, MACD histogram changes, and Stochastic crossovers as reversal signals. The overall neutral-to-sell rating calls for caution until bullish confirmation appears.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.

Related Ticker: HEI

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


HEI sees its Stochastic Oscillator ascending out of oversold territory

On September 22, 2026, the Stochastic Oscillator for HEI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 52 instances where the indicator left the oversold zone. In 34 of the 52 cases the stock moved higher in the following days. This puts the odds of a move higher at over 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HEI's RSI Indicator exited the oversold zone, 12 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.

The Moving Average Convergence Divergence (MACD) for HEI just turned positive on September 23, 2026. Looking at past instances where HEI's MACD turned positive, the stock continued to rise in 30 of 47 cases over the following month. The odds of a continued upward trend are 64%.

Following a +2.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where HEI advanced for three days, in 214 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HEI as a result. In 47 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.

The 10-day moving average for HEI crossed bearishly below the 50-day moving average on August 31, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HEI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

The Aroon Indicator for HEI entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 24 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock better than average.

The Tickeron Seasonality Score of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. HEI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.606) is normal, around the industry mean (6.305). P/E Ratio (50.768) is within average values for comparable stocks, (58.116). Projected Growth (PEG Ratio) (2.092) is also within normal values, averaging (2.564). Dividend Yield (0.001) settles around the average of (0.009) among similar stocks. P/S Ratio (8.163) is also within normal values, averaging (18.330).

The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 38.94B. The market cap for tickers in the group ranges from 4.49 to 1.92T. SPCX holds the highest valuation in this group at 1.92T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -1%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -11%. SPCX experienced the highest price growth at 18%, while PUSA experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 70
Price Growth Rating: 62
SMR Rating: 77
Profit Risk Rating: 76
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
HEI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of aerospace products and services

Industry AerospaceDefense

Industry
Aerospace And Defense
Address
3000 Taft Street
Phone
+1 954 987-4000
Employees
11100
Web
https://www.heico.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.